EP Patent

EP2600839B1 — Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cylohexane-1,1'-pyrano[3,4,b]indol]-4-amine

Assigned to Gruenenthal GmbH · Expires 2018-01-10 · 8y expired

What this patent protects

Patent listed against Prograf.

Drugs covered by this patent

Patent Metadata

Patent number
EP2600839B1
Jurisdiction
EP
Classification
—
Expires
2018-01-10
Drug substance claim
No
Drug product claim
No
Assignee
Gruenenthal GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.